Introduction to High-Risk NMIBC Management

Bladder cancer remains a significant global health burden, with over 75% of cases diagnosed as non-muscle-invasive bladder cancer (NMIBC). Currently, clinicians consider intravesical Bacillus Calmette-Guérin (BCG) the gold standard for high-risk patients. However, many patients eventually experience disease recurrence. Consequently, researchers are investigating new strategies like combining BCG and immune checkpoint inhibitors to enhance treatment efficacy and support durable bladder preservation.

Biological Rationale for Synergy

The combination of these therapies rests on a strong immunological foundation. BCG acts as a primary primer by recruiting innate and adaptive immune cells to the bladder microenvironment. Furthermore, it increases the expression of programmed death-ligand 1 (PD-L1) on tumor cells. Therefore, adding an immune checkpoint inhibitor (ICI) can counteract the functional exhaustion of these BCG-induced T-cells. This synergy potentially creates a more robust and sustained antitumor response compared to monotherapy.

Clinical Evidence for BCG and Immune Checkpoint Inhibitors

Early-phase studies, such as the KEYNOTE-057 trial, led to the approval of pembrolizumab for BCG-unresponsive NMIBC. More recently, the Phase III POTOMAC trial evaluated durvalumab in combination with BCG induction and maintenance. Results indicated a 32% reduction in the risk of high-risk disease recurrence or death. However, other trials like ALBAN have shown that upfront combinations do not always yield superior oncological outcomes. Consequently, the clinical evidence remains heterogeneous, and the medical community awaits more mature data before adopting these regimens into routine practice.

Future Directions and Challenges

Despite the strong biological rationale, translating these findings into consistent clinical benefit is difficult. Researchers must identify validated predictive biomarkers to select patients who will most likely benefit from the combination. Additionally, clinicians must balance the potential efficacy gains against the risk of systemic toxicities from immunotherapy. Future guidelines will likely depend on clear demonstrations of superiority over established bladder-preserving strategies.

Frequently Asked Questions

How do BCG and immune checkpoint inhibitors work together?

BCG primes the immune system by attracting immune cells to the bladder, while immune checkpoint inhibitors prevent those cells from becoming exhausted, allowing for a more effective attack on cancer cells.

Is this combination treatment currently the standard of care?

No, the combination remains largely investigational. While some ICIs are approved for BCG-unresponsive disease, their use as an upfront combination with BCG requires further validation through mature Phase III evidence.

What were the main findings of the POTOMAC trial?

The POTOMAC trial demonstrated that adding durvalumab to BCG maintenance therapy significantly improved disease-free survival in patients with high-risk NMIBC compared to BCG alone.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical judgment, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Musone M et al. Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer. Oncol Ther. 2026 Jun 11. doi: 10.1007/s40487-026-00445-8. PMID: 42277549.

De Santis M et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet. 2025 Nov 8;406(10516):2221-2234.

Balar AV et al. Pembrolizumab for the treatment of bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer (KEYNOTE-057): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2021 Jul;22(7):919-930.